1. Home
  2. MIST vs ANIX Comparison

MIST vs ANIX Comparison

Compare MIST & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.70

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.63

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIST
ANIX
Founded
2003
1982
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.3M
114.0M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
MIST
ANIX
Price
$0.70
$2.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$5.86
★ $9.75
AVG Volume (30 Days)
★ 1.1M
267.0K
Earning Date
11-11-2026
09-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.82
EPS
N/A
★ N/A
Revenue
N/A
★ $210,000.00
Revenue This Year
$147.62
N/A
Revenue Next Year
$476.43
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$2.32
52 Week High
$3.06
$5.46

Technical Indicators

Market Signals
Indicator
MIST
ANIX
Relative Strength Index (RSI) 34.67 39.72
Support Level N/A $2.62
Resistance Level $1.42 $3.09
Average True Range (ATR) 0.06 0.14
MACD 0.00 -0.01
Stochastic Oscillator 8.54 6.69

Price Performance

Historical Comparison
MIST
ANIX

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: